%---------------------------------------------------------------------------

\begin{table*}[]
\small
  \centering
   \caption{Treatment efficacy on alcohol use reduction}
  \label{tab:e1}
\begin{tabular}{lllclclll}
 \hline
 &&&&&&&\\
& 
\pbox{2cm}{Sample\\characteristics} &
\pbox{1cm}{Design\\} &
\pbox{2cm}{Study\\Timeframe} &
\pbox{1.5cm}{Treatment\\protocol} &
 & 
\pbox{2cm}{Primary\\outcome\\measures} & 
\pbox{2cm}{Results\\} \\
&&&&&&&\\
&
Size ($\dagger$)
&
&
\emph{(weeks)}&
Dosage &
Duration &
&
\\
 \hline
%------------------------------------------------------------
&&&&&&&\\
\pbox{3cm}{Sellers 1994\\ \cite{sellers_clinical_1994}}
& \pbox{1cm}{74 (A)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{9\\}
& \pbox{3cm}{OND:\\ 0.25 mg \\2mg} 
& \pbox{1cm}{6 w\\}
& \pbox{2cm}{DDD\\(standard drink 13g)} 
& \pbox{4cm}{Principal analysis: trend but N.S.;\\\textit{Post hoc} analysis: effective when heavy drinkers (>10DD) excluded *} \\
%-----------------------------
%&&&&&&&\\
\pbox{3cm}{Johnson 2000a\\ \cite{johnson_combining_2000}}
& \pbox{1cm}{20 (B)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{8\\}
& \pbox{3cm}{OND\\ 4 µg/kg bid\\+NAL\\ 25 mg bid}
& \pbox{1cm}{8 w\\}
& \pbox{2cm}{DD, DDD and PDA\\}
& \pbox{4cm}{Reduced DD*, DDD* and PDA (N.S) compared to placebo}\\
%-------------------------------
%&&&&&&&\\
\pbox{3cm}{Johnson 2000b\\ \cite{johnson_ondansetron_2000}}
& \pbox{1cm}{321 (C)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{12\\}
& \pbox{3cm}{OND:\\ 1 µg/kg bid\\ 4 µg/kg bid\\ 16 µg/kg bid}
& \pbox{1cm}{11 w\\}
& \pbox{2cm}{DD, DDD, PDA and plasma CDT (standard drink 12 g)}
& \pbox{4cm}{In EOA, OND was superior* to placebo on DD, DDD for all dosage and on CDT for 1 and 4 µg/kg bid. OND at 4µg/kg bid was superior to placebo on PDA and DAW}\\
%-----------------------------
%&&&&&&&\\
\pbox{3cm}{Ait-Daoud 2001b\\ \cite{ait-daoud_combining_2001-1}}
& \pbox{1cm}{20 (B)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{8\\}
& \pbox{3cm}{OND\\ 4 µg/kg bid\\+NAL\\ 50 mg}
& \pbox{1cm}{8 w\\}
& \pbox{2cm}{log serum CDT\\}
& \pbox{4cm}{EOA treated with OND+NAL had lower CDT levels compared to placebo*}\\
%----------------------------------------
%&&&&&&&\\
\pbox{3cm}{Kranzler 2003\\ \cite{kranzler_effects_2003}}
& \pbox{1cm}{40 (D)\\}
& \pbox{1cm}{PT\\}
& \pbox{1cm}{8\\}
& \pbox{3cm}{OND:\\ 4 µg/kg bid}
& \pbox{1cm}{8 w\\}
& \pbox{2cm}{DD, DDD, DrInC score, log CDT ratio}
& \pbox{4cm}{EOA had greater* decrease in DD, DDD and alcohol related problems than LOA}\\
%-----------------------------
%&&&&&&&\\
\pbox{3cm}{Kenna 2009\\\cite{kenna_within-group_2009}}
& \pbox{1cm}{20 (G)\\} %but 15 evaluated
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{8\\}
& \pbox{3cm}{SER\\ 200 mg\\OND\\ 0.5 mg}
& \pbox{1cm}{2/3 w\\}
& \pbox{2cm}{ASAE volume (mL), DDD}
& \pbox{4cm}{In L/L, OND reduced* ASAE alcohol volume and DDD compared to SER}\\
%----------------------------------------
%&&&&&&&\\
\pbox{3cm}{Johnson 2011\\ \cite{johnson_pharmacogenetic_2011}}
& \pbox{1cm}{283 (H)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{13\\}
& \pbox{3cm}{OND:\\ 4 µg/kg bid}
& \pbox{1cm}{11 w\\}
& \pbox{2cm}{DDD, PDA\\}
& \pbox{4cm}{In L/L, less DDD and higher PDA in OND vs. placebo*; In OND, less DDD and higher PDA in L/L vs L-S/S}\\
%-----------------------------
%&&&&&&&\\
\pbox{3cm}{Corrêa Filho 2013\\\cite{correa_filho_pilot_2013}}
& \pbox{1cm}{102 (I)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{12\\}
& \pbox{3cm}{OND:\\ 16 mg\\} 
& \pbox{1cm}{12 w\\}
& \pbox{2cm}{PDA, PHDD\\(standard drink 14g)} 
& \pbox{4cm}{OND was superior than placebo to reduce \%HDD *}\\ 
%------------------------------
%&&&&&&&\\
\pbox{3cm}{Kenna 2014a\\
\cite{kenna_ondansetron_2014-1}}
& \pbox{1cm}{77 (J)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{9\\}
& \pbox{3cm}{SER\\ 200 mg\\or OND\\ 0.5 mg}
& \pbox{1cm}{3 w\\}
& \pbox{2cm}{ASAE volume (mL), DDD}
& \pbox{4cm}{OND resulted in reduction in DDD compared to SER*}\\
%----------------------------------------
%&&&&&&&\\
\pbox{3cm}{Kenna 2014b\\ \cite{kenna_ondansetron_2014}}
& \pbox{1cm}{77 (J)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{9\\}
& \pbox{3cm}{SER\\ 200 mg\\or OND\\ 0.5 mg}
& \pbox{1cm}{3 w\\}
& \pbox{2cm}{ASAE volume (mL), DDD}
& \pbox{4cm}{Among women only, L/L + OND and L-S/S + SER had fewer DDD* and reduced ASAE* L/L + SER and L-S/L + OND\\}\\
%----------------------------------------
%-----------------------------
%&&&&&&&\\
\pbox{3cm}{Sherwood 2021\\ \cite{sherwood_brown_randomized_2021}}
& \pbox{1cm}{70 (K)\\}
& \pbox{1cm}{RCT\\}
& \pbox{1cm}{12\\}
& \pbox{3cm}{OND\\0.5/1/2 or 4 mg\\(3.23 ± 2.64 mg)}
& \pbox{1cm}{12 w\\}
& \pbox{2cm}{TLFB, GGT, CDT}
& \pbox{4cm}{Trend in lower self-reported alcohol use in ondansetron group vs placebo (N.S.)}\\
%----------------------------------------
%-----------------------------
&&&&&&&\\
 \hline
\end{tabular}
\caption*{\emph{\input{other/legends}}}
\end{table*}
%---------------------------------------------------------------------------
